Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-20
Steven R. Post
Federal Grant PI
High Impact
Vice Chair for Research
Also affiliated: Rutgers, The State University of New Jersey (2001); The Graduate Center, CUNY (2009); Edgewood University (1994); University of Louisville (1998); University of Kentucky (1999–2013); Johns Hopkins University (2001); University of California, Irvine (2001); University of Arkansas Medical Center (2015–2026); Cancer Institute (WIA) (2025); University of California San Diego (1995–2003); University of Illinois Chicago (1992–1993); University of Chicago (1992–1993); Arkansas Cardiology (2014); Winthrop Rockefeller Foundation (2019–2026); Arkansas Department of Agriculture (2014–2016)
Faculty Researcher
Pathology, College of Medicine
33 h-index
132 pubs
4,568 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Steven R. Post's research focuses on the intersection of viral infections, cellular signaling pathways, and cancer development. He investigates how oncogenic viruses, such as Human Herpesvirus 8 (KSHV), interact with host cells and how external factors, including antiviral drugs and SARS-CoV-2, can influence their behavior. Dr. Post has examined the role of specific cellular networks, like the EIF4G1 network, in the survival and progression of non-small cell lung cancers (NSCLC).
His work also explores potential therapeutic strategies. This includes characterizing novel oncolytic virotherapy platforms for liver cancers, evaluating agents like echinomycin for KSHV-related malignancies, and repurposing existing vaccines for cancer immunotherapy. Dr. Post has received federal funding from the NIH/National Cancer Institute for research into how periodontal bacteria may enhance KSHV pathogenesis and Kaposi's Sarcoma development in HIV-positive patients. He leads a research group and maintains an active lab website, collaborating with colleagues at the University of Arkansas for Medical Sciences.
Metrics
- h-index: 33
- Publications: 132
- Citations: 4,568
Selected Publications
-
Repurposing Monensin and Its Derivatives as Immune-Modulatory Candidates for Metastatic Breast Cancer (Abstract ID: 231537) (2026)
-
Abstract 2908: SR-A antagonism remodels the myeloid population of tumor immune microenvironment, expands CD8-positive T cells, and enhances antitumor efficacy in vivo (2026)
-
Detection of mitochondrial DNA mutations in T cells following 5-FU or cisplatin exposure (2026)
-
Class A scavenger receptors promote tumor progression and induce a unique macrophage phenotype in a mouse model of spontaneous breast cancer (2026)
-
Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2026)
-
Evaluation of the Activity of Monensin and Its Analogs for Modulation of Stem-like Cell Functionality in 2D and 3D Breast Cancer Models (2025)
-
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)
-
Impact of New Hematopoietic Progenitor Cell Collection Goals on Apheresis and Cell Therapy Laboratory Services (2025)
-
Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model (2025)
-
Isolation of mitochondrial mutation-specific T cell receptors (2025)
-
Abstract 2987: Role of EIF4G1 network in non-small cell lung cancers (NSCLC) pathogenesis and development of targeted therapy (2025)
-
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2025)
-
Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma (2025)
-
Monensin and Its Analogs Offer a Multi-Targeted Approach to Enhancing Metastatic Breast Cancer Immunogenicity and Cell Death (Abstract ID: 163059) (2025)
-
474 Repositioning monensin: Enhancing anti-cancer activity and immune modulation in breast cancer cells (2025)
Federal Grants 1 $324,563 total
NIH
Contact PI
Mar 2019 - Apr 2025
Research Interests
The goal of our research is to better understand the key role that macrophages play in the development and progression of chronic inflammatory diseases including cardiovascular disease and cancer. Our studies indicate that a specific macrophage receptor, the class A macrophage scavenger receptor (SR-A), may differentially function to enhance or diminish inflammation. Our ongoing studies seek to provide mechanistic details regarding the functional interactions between SR-A and inflammatory signaling pathways. Results of these studies will advance understanding of the pathologic role of macrophages in cardiovascular disease and cancer, and may indicate novel therapeutic approaches targeting the inflammatory responses in these disease.
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- Impact of hemodynamics on efferocytosis in endothelial cells NIH/Nat. Heart, Lung & Blood Institute Co-Investigator
- Diabetes Medicine Adherence in Marshallese Patients UAMS College of Medicine Principal Investigator
- Periodontal bacteria enhance oral KSHV pathogenesis and Kaposi's Sarcoma development in HIV + patients - Continuation NIH/Nat. Cancer Institute Co-Investigator
- Fibroblast-macrophage interactions induce a tumor-promoting microenvironment NIH/National Institutes of Health Principal Investigator
- Regulation of Ras Signaling by Rlf in Hypertrophy NIH/Nat. Heart, Lung & Blood Institute Principal Investigator
- SR-A as a therapeutic target in breast cancer NIH/Nat. Cancer Institute Principal Investigator
- Function and Regulation of SR-A in Atherosclerosis NIH/Nat. Heart, Lung & Blood Institute Principal Investigator
- Platelet-leukocyte regulation of inflammatory responses- Resubmission- Resubmission American Heart Association Principal Investigator
- Leukocyte-platelet modulation of the systemic inflammatory response NIH Co-Principal Investigator
Collaboration Network
Top Collaborators
Thomas J. Kelly
University of Arkansas for Medical Sciences
13 shared publications
In database
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen
- Partnership in Cancer Research (PCAR) Program Increases Medical Student Knowledge and Confidence to Perform Cancer Research
- The Tumor Microenvironment and Immune Response in Breast Cancer
Showing 5 of 13 shared publications
Lu Dai
University of Arkansas for Medical Sciences
10 shared publications
In database
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- SARS‐CoV‐2 infection and lytic reactivation of herpesviruses: A potential threat in the postpandemic era?
- The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways
- Role of EIF4G1 network in non‐small cell lung cancers (NSCLC) cell survival and disease progression
- Echinomycin as a promising therapeutic agent against KSHV-related malignancies
Showing 5 of 10 shared publications
Jungang Chen
University of Arkansas for Medical Sciences (US)
10 shared publications
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- SARS‐CoV‐2 infection and lytic reactivation of herpesviruses: A potential threat in the postpandemic era?
- The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways
- Role of EIF4G1 network in non‐small cell lung cancers (NSCLC) cell survival and disease progression
- Echinomycin as a promising therapeutic agent against KSHV-related malignancies
Showing 5 of 10 shared publications
Zhiqiang Qin
University of Arkansas for Medical Sciences (US)
10 shared publications
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- SARS‐CoV‐2 infection and lytic reactivation of herpesviruses: A potential threat in the postpandemic era?
- The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways
- Role of EIF4G1 network in non‐small cell lung cancers (NSCLC) cell survival and disease progression
- Echinomycin as a promising therapeutic agent against KSHV-related malignancies
Showing 5 of 10 shared publications
Bolni Marius Nagalo
University of Arkansas for Medical Sciences
10 shared publications
In database
- Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers
- Partnership in Cancer Research (PCAR) Program Increases Medical Student Knowledge and Confidence to Perform Cancer Research
Showing 5 of 10 shared publications
Camila Simões
University of Arkansas for Medical Sciences
9 shared publications
In database
- Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers
Showing 5 of 9 shared publications
Martin J. Cannon
University of Arkansas for Medical Sciences
9 shared publications
In database
- Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
Showing 5 of 9 shared publications
Alexei G. Basnakian
University of Arkansas for Medical Sciences
8 shared publications
In database
- Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
Showing 5 of 8 shared publications
Mulu Z. Tesfay
University of Arkansas for Medical Sciences
8 shared publications
In database
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma
Showing 5 of 8 shared publications
Khandoker Usran Ferdous
University of Arkansas for Medical Sciences
8 shared publications
In database
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma
Showing 5 of 8 shared publications
Alicja Urbaniak
Cancer Institute (WIA)
8 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- 474 Repositioning monensin: Enhancing anti-cancer activity and immune modulation in breast cancer cells
- Monensin and Its Analogs Offer a Multi-Targeted Approach to Enhancing Metastatic Breast Cancer Immunogenicity and Cell Death (Abstract ID: 163059)
- Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma
- Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model
Showing 5 of 8 shared publications
Jean Christopher Chamcheu
Southern University and Agricultural and Mechanical College (US)
7 shared publications
- Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers
Showing 5 of 7 shared publications
Eric R. Siegel
University of Arkansas for Medical Sciences
7 shared publications
In database
- VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen
- 474 Repositioning monensin: Enhancing anti-cancer activity and immune modulation in breast cancer cells
- Monensin and Its Analogs Offer a Multi-Targeted Approach to Enhancing Metastatic Breast Cancer Immunogenicity and Cell Death (Abstract ID: 163059)
- Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
Showing 5 of 7 shared publications
Aleksandra Cios
Winthrop Rockefeller Foundation (US)
7 shared publications
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
Showing 5 of 7 shared publications
Randal S. Shelton
University of Arkansas for Medical Sciences
6 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
Showing 5 of 6 shared publications
Similar Researchers
Based on overlapping research topics
Jiao Song
University of Arkansas for Medical Sciences
Herpesvirus Infections and Treatments
SARS-CoV-2 and COVID-19 Research
Cancer-related molecular mechanisms research
Lindsey Barrett
University of Arkansas for Medical Sciences
Herpesvirus Infections and Treatments
SARS-CoV-2 and COVID-19 Research
Cancer-related molecular mechanisms research
Yuchun Du
University of Arkansas at Fayetteville
Cancer-related molecular mechanisms research
Host-Pathogen Interactions
Cancer Treatment and Pharmacology
J. Craig Forrest
University of Arkansas for Medical Sciences
Herpesvirus Infections and Treatments
SARS-CoV-2 and COVID-19 Research
Cancer-related molecular mechanisms research
Shana M. Owens
University of Arkansas for Medical Sciences
Herpesvirus Infections and Treatments
SARS-CoV-2 and COVID-19 Research
Host-Pathogen Interactions
Justine R Bersonda
University of Arkansas for Medical Sciences
Herpesvirus Infections and Treatments
Cancer-related molecular mechanisms research
Host-Pathogen Interactions